Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Oversight Of Rx Compounding Should Increase, GAO Study Suggests

Executive Summary

Increased FDA oversight of pharmacy compounding may be necessary due to state budgetary constraints, an Oct. 23 General Accounting Office report suggests

You may also be interested in...



FDA Warns Compounding Pharmacies On Ribavirin, Propulsid Versions

A recent spate of enforcement actions by FDA against compounding pharmacies includes citations for compounded versions of ribavirin and Propulsid

FDA Warns Compounding Pharmacies On Ribavirin, Propulsid Versions

A recent spate of enforcement actions by FDA against compounding pharmacies includes citations for compounded versions of ribavirin and Propulsid

FDA Advisory Committee Line-Up Shrinks With Elimination Of Two Panels

FDA will reduce its total advisory committee count to 30 with the termination of the Pharmacy Compounding and Medical Imaging Drugs Advisory Committees

Related Content

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel